Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864094 | 0.95 | KCNA5 (0.38) | KCNA5GRM2CYP19A1CYP17A1FFAR1 | |
| SCHEMBL1975341 | 0.88 | CCNC (0.36) | CYP19A1CYP17A1CHRNB2CHRNA4GRIN1 | |
| SCHEMBL1972925 | 0.86 | KMT2A (0.35) | CYP19A1CYP17A1FFAR1CHRNB2CHRNA4 | |
| SCHEMBL1974023 | 0.84 | CYP19A1 (0.36) | CYP19A1CYP17A1FFAR1CHRNB4CHRNA3 | |
| SCHEMBL1975867 | 0.83 | KMT2A (0.36) | CYP19A1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL1976002 | 0.82 | CHRNB2 (0.35) | CHRNB2CHRNA4GRIN1GRIN2B | |
| SCHEMBL1972019 | 0.82 | CHRNB2 (0.35) | CHRNB2CHRNA4GRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL4858247 | 0.82 | KMT2A (0.35) | CYP19A1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL1973033 | 0.81 | CHRNB2 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4GRIN1 | |
| SCHEMBL1975703 | 0.80 | CCNC (0.37) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668021-B1 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | FOURNIER LAB SA (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-7470671-B2 | Thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therapeutics | LABORATOIRE FOURNIER (FR) | 2008-12-30 | — | — | US | disclosed |
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | LABORATOIRES FOURNIER S.A. (FR) | 2007-03-08 | — | — | US | disclosed |
| EP-1668021-A2 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | LABORATOIRES FOURNIER S.A. (FR) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030785-A2 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | LABORATOIRES FOURNIER S.A. (FR) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | NOTUM, STS, AGPS | KCNA5 2412/4885GRM2 3827/4885CYP19A1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.